Researchers Show Eye Drop Vehicle Can Deliver Anti-VEGF to Retina

July 27, 2018: By Joan McKenna

Scientists have shown their drug delivery vehicle effectively delivers Avastin and Lucentis to the back of the eye in rabbits and pigs, the UK’s University of Birmingham announced July 23. The research was led by Felicity de Cogan, PhD.

The team is now working with Macregen, of San Jose, California, which has licensed the technology, to develop therapies for age-related macular degeneration and other eye diseases.

Macregen’s own drug candidate, Mitia, is intended to remove and/or clear accumulated lipids under the macula that are the main component of drusen deposits typically observed in patients with dry AMD.

Macregen says it envisions Mitia being used in combination with anti-VEGF drugs that are designed to treat neovascular AMD. Thus, both the removal of lipid deposits and the inhibition of neovascular complications may be accomplished concurrently or sequentially.

Cogan’s team used a cell-penetrating peptide to deliver drugs to the back of the eye.

The combined team is now expediting proof of concept studies and says clinical trials could start as early as spring 2019.

Results of the rabbit and pig study were published under an open access license in the July 2018 issue of IOVS.

 

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Astellas Acquires Quethera, Glaucoma Gene Therapy Candidate in Potential $109 Million Deal

STAAR Surgical Completes $77.9 Million Public Offering

Rheon’s eyeWatch Adjustable Glaucoma Device Implanted in Three UK Patients

Carl Zeiss Meditec Revenues Total $356 Million in Third Quarter of FY2018, a 12.7 Percent Increase

Kedalion Therapeutics Raises $5 Million in Series A Financing

Second Sight Reports 17 Argus II Implantations in Q2-2018; Firm to Focus on Orion System

Iridex Revenues Grow 3 Percent in Q2-2018

Omeros Revenues Drop Steeply with Omidria’s Temporary Loss of Pass-through Status

Shire’s Xiidra Delivers $100 Million in Q2-2018 Revenues, an Increase of 75 Percent

STAAR Posts Q2-2018 Revenues of $33.9 Million, a 55 Percent Increase

Avedro Names Glaukos CEO Thomas Burns to its Board

Aerie Licenses DSM’s Bioerodible Implant Technology for Ophthalmic Use for $15 Million

Alimera’s Q2-2018 Revenues Increase 5 Percent

Presbyopia Therapies’ PRX Meets Phase IIb Endpoints

Clinical Study of Imprimis’ Dropless Formulation Set to Begin in Canada

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT